PDCD1 and hematologic disorder: Indeed, although the combination of anti-PD-1 with anti-CTLA-4 did not show a greater clinical response than anti-PD-1 alone for the treatment of hematological malignancies [105], many other combinations of ICB therapy are currently under investigation in NHL patients [99].